FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention refers to a pharmaceutical composition, namely a pharmaceutical composition for treating dementia and moderate cognitive disorders. Pharmaceutical composition for treating dementia and moderate cognitive disorders, containing a compound of formula (1):
or N-[3-((4aS,5R,7aS)-2-amino-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxamide, or a pharmaceutically acceptable salt thereof and a salt of a compound containing an aliphatic saturated C12-22 hydrocarbon group, where the salt of the compound containing an aliphatic saturated C12-22-hydrocarbon group is at least one salt selected from a group consisting of a salt of an aliphatic saturated organic C12-22-acid and metal, alkali metal mono-C12-22-alkyl fumarate monosalt and alkali-earth metal mono-C12-22-alkyl fumarate monosalt containing an aliphatic saturated C12-22-hydrocarbon group to total weight of the pharmaceutical composition from 0.1 wt. % to 10 wt. %.
EFFECT: above described pharmaceutical composition enables to ensure no significant change in the dissolution profile, even after storage for a certain period of time.
9 cl, 12 dwg, 15 tbl, 26 ex
